Atezolizumab for advanced lung cancer with high PD-L1
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called atezolizumab, an immunotherapy that helps your immune system fight cancer, in people with advanced non-small cell lung cancer that has high PD-L1 protein (≥50%) and no treatable gene mutations. Researchers will also check a blood marker (c-FLIP) linked to certain immune cells to understand how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You can be up and about for at least half the day (ECOG 0-2)
- Your lung cancer has spread and you haven't yet received treatment for this advanced stage
- Your tumor has a high PD-L1 protein level (at least 50% on a standard test)
- Your cancer does not have a 'driver' mutation (like EGFR or ALK) that can be treated with a targeted therapy
- You have at least one tumor that can be measured on a scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.